Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 1 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 1 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER vs INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Peritoneal dialysis solution with dextrose as osmotic agent; dextrose creates osmotic gradient across peritoneal membrane to remove excess fluid and uremic toxins.
Inpersol-LC/LM with 3.5% dextrose is a peritoneal dialysis solution that provides osmotic ultrafiltration via dextrose, removing waste products and excess fluid from the blood across the peritoneal membrane. The low calcium (LC) and low magnesium (LM) formulations adjust electrolyte concentrations to manage imbalances.
Intraperitoneal administration via automated peritoneal dialysis (APD) or continuous ambulatory peritoneal dialysis (CAPD); typical adult dose is 2-3 liters per exchange, 4-5 exchanges per day (CAPD) or 8-12 liters total volume per night (APD).
Intraperitoneal administration: 2 to 2.5 liters per exchange, 4 to 5 exchanges per day, as prescribed by physician based on peritoneal equilibration test.
None Documented
None Documented
Not applicable: Dextrose absorbed from peritoneal dialysate has a half-life similar to IV glucose (approx. 1-2 hours), but as a dialysis solution, the concept of terminal elimination half-life is not defined for the non-absorbed components. Clinical context: continuous intraperitoneal administration.
Not applicable; dextrose is continuously infused and removed; the half-life of intraperitoneal dextrose is approximately 1-2 hours due to rapid absorption and metabolism, with clinically relevant hyperglycemia managed by insulin.
Peritoneal dialysis fluid: DIALYTE components (electrolytes, dextrose) are not systemically absorbed in clinically significant amounts; dextrose is partially absorbed across the peritoneum and metabolized. Renal and biliary excretion are not relevant as this is a topical intraperitoneal solution. Elimination of absorbed dextrose follows glucose metabolism (oxidation, storage).
Renal (via peritoneal dialysis effluent); approximately 60-70% of administered dextrose is absorbed and metabolized, with the remainder removed in dialysate; no significant biliary/fecal elimination.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution